enGene Announces Partnership with Janssen Biotech to Develop New Therapies for Inflammatory Bowel Diseases

enGene Announces Partnership with Janssen Biotech to Develop New Therapies for Inflammatory Bowel Diseases
enGene, Inc., a privately held biotechnology company developing a versatile non-viral vector platform for gene delivery through its proprietary technology “Gene Pill”, recently announced that it has made a decisive agreement with Janssen Biotech, Inc. for the development and commercialization of new treatments for patients with inflammatory bowel diseases (IBD). Under the terms of the

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *